Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Tedizolid phosphate (sivextro): a second-generation oxazolidinone to treat acute bacterial skin and skin structure infections.

Literature DB >> 25136252

Tedizolid phosphate (sivextro): a second-generation oxazolidinone to treat acute bacterial skin and skin structure infections.

Elaine Wong, Saba Rab.

Abstract

Tedizolid phosphate: a second-generation oxazolidinone for acute bacterial skin and skin structure infections.

Entities: Chemical Disease

Year: 2014 PMID： 25136252 PMCID： PMC4123804

Source DB: PubMed Journal: P T ISSN： 1052-1372

17 in total

1. In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococci.

Authors: Iciar Rodríguez-Avial; Esther Culebras; Carmen Betriu; Gracia Morales; Irene Pena; Juan J Picazo
Journal: J Antimicrob Chemother Date: 2011-09-27 Impact factor: 5.790

2. Practice guidelines for the diagnosis and management of skin and soft-tissue infections.

Authors: Dennis L Stevens; Alan L Bisno; Henry F Chambers; E Dale Everett; Patchen Dellinger; Ellie J C Goldstein; Sherwood L Gorbach; Jan V Hirschmann; Edward L Kaplan; Jose G Montoya; James C Wade
Journal: Clin Infect Dis Date: 2005-10-14 Impact factor: 9.079

3. Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers.

Authors: Seth T Housman; J Samuel Pope; John Russomanno; Edward Salerno; Eric Shore; Joseph L Kuti; David P Nicolau
Journal: Antimicrob Agents Chemother Date: 2012-02-13 Impact factor: 5.191

4. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial.

Authors: Gregory J Moran; Edward Fang; G Ralph Corey; Anita F Das; Carisa De Anda; Philippe Prokocimer
Journal: Lancet Infect Dis Date: 2014-06-05 Impact factor: 25.071

5. Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections.

Authors: P Prokocimer; P Bien; J Surber; P Mehra; C DeAnda; J B Bulitta; G R Corey
Journal: Antimicrob Agents Chemother Date: 2010-11-29 Impact factor: 5.191

6. Activity of tedizolid phosphate (TR-701) in murine models of infection with penicillin-resistant and penicillin-sensitive Streptococcus pneumoniae.

Authors: Sunghak Choi; Weonbin Im; Ken Bartizal
Journal: Antimicrob Agents Chemother Date: 2012-06-19 Impact factor: 5.191

Review 7. Tedizolid (TR-701): a new oxazolidinone with enhanced potency.

Authors: Zeina A Kanafani; G Ralph Corey
Journal: Expert Opin Investig Drugs Date: 2012-02-13 Impact factor: 6.206

8. In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions.

Authors: S Flanagan; K Bartizal; S L Minassian; E Fang; P Prokocimer
Journal: Antimicrob Agents Chemother Date: 2013-04-22 Impact factor: 5.191

9. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial.

Authors: Philippe Prokocimer; Carisa De Anda; Edward Fang; Purvi Mehra; Anita Das
Journal: JAMA Date: 2013-02-13 Impact factor: 56.272

10. Staphylococcus aureus-associated skin and soft tissue infections in ambulatory care.

Authors: Linda F McCaig; L Clifford McDonald; Sanjay Mandal; Daniel B Jernigan
Journal: Emerg Infect Dis Date: 2006-11 Impact factor: 6.883

12 in total

Review 1. Community-associated methicillin-resistant Staphylococcus aureus infection: Literature review and clinical update.

Authors: Kassandra Loewen; Yoko Schreiber; Mike Kirlew; Natalie Bocking; Len Kelly
Journal: Can Fam Physician Date: 2017-07 Impact factor: 3.275

2. Radiolabeled Tedizolid Phosphate Liposomes for Topical Application: Design, Characterization, and Evaluation of Cellular Binding Capacity.

Authors: Merve Karpuz; Evren Atlihan-Gundogdu; E Selin Demir; Zeynep Senyigit
Journal: AAPS PharmSciTech Date: 2021-02-02 Impact factor: 3.246

3. In Vitro and In Vivo Activities of a Bi-Aryl Oxazolidinone, RBx 11760, against Gram-Positive Bacteria.

Authors: Tarani Kanta Barman; Manoj Kumar; Tarun Mathur; Tridib Chaira; G Ramkumar; Vandana Kalia; Madhvi Rao; Manisha Pandya; Ajay Singh Yadav; Biswajit Das; Dilip J Upadhyay; Rituraj Konwar; V Samuel Raj; Harpal Singh
Journal: Antimicrob Agents Chemother Date: 2016-11-21 Impact factor: 5.191

Review 4. Destination of aminoglycoside antibiotics in the 'post-antibiotic era'.

Authors: Yoshiaki Takahashi; Masayuki Igarashi
Journal: J Antibiot (Tokyo) Date: 2017-10-25 Impact factor: 2.649

5. Pharmacokinetics of Tedizolid in Plasma and Sputum of Adults with Cystic Fibrosis.

Authors: A Young J Park; Joshua Wang; Jordanna Jayne; Lynn Fukushima; Adupa P Rao; David Z D'Argenio; Paul M Beringer
Journal: Antimicrob Agents Chemother Date: 2018-08-27 Impact factor: 5.191

6. In Vitro and In Vivo Activities of DS-2969b, a Novel GyrB Inhibitor, and Its Water-Soluble Prodrug, DS11960558, against Methicillin-Resistant Staphylococcus aureus.

Authors: Tarani Kanta Barman; Manoj Kumar; Tarun Mathur; Eiko Namba; Diksha Singh; Tridib Chaira; Yuichi Kurosaka; Makiko Yamada; Dilip Jatashankar Upadhyay; Nobuhisa Masuda
Journal: Antimicrob Agents Chemother Date: 2018-05-25 Impact factor: 5.191